ASH Clinical News June 2015 | Page 37

FEATURE A Day on the Hill: The ASH Committee on Practice Goes to Washington O n May 19, 2015, following its spring meeting in Washington, DC, members of the ASH Committee on Practice visited more than 40 congressional offices to advocate for legislation to ensure access to safe and effective hematologic drugs, as well as to urge the Centers for Medicare and Medicaid Services (CMS) to take a closer look at outpatient evaluation and management codes for physicians who primarily treat chronically ill patients. For more about these initiatives, see the SIDEBARS on pages 36 and 37. ASH Committee on Practice members split up into six groups to cover the most ground. ASH Clinical News tagged along with Harriet A. Bering, MD, Chancellor Donald, MD, and Judith Kleinerman, MD, as they met with Senators, Representatives, and staffers to spread the word about insurance parity for oral cancer drugs, evaluation and management (E&M) codes, and other hematology issues that affect patients and providers. On May 18, the day before hitting the Hill, the Committee members were briefed about the Cancer Drug Coverage Parity Act by Leslie Brady, legislative assistant in the Office of Congressman Brian Higgins (D-NY-26), a co-sponsor of the bill. Ms. Brady shared Congress’ plans to reintroduce oral chemotherapy parity legislation and provided some suggestions on how ASH can urge support for this legislation through its advocacy activities. Leslie Brady, from Rep. Higgin’s office, briefs the Committee on Practice members on the Cancer Drug Coverage Parity Act. PHOTO DIARY May 19, 8:00 a.m.: The day starts with breakfast and a strategy meeting at ASH headquarters, including a review of the schedule and the goals for the day. 9:15 a.m.: The groups depart for Capitol Hill! Left to right: Drs. Bering, Donald, and Kleinerman 9:30 a.m.: Drs. Bering and Kleinerman meet with Melea Atkins, a legislative aide from Senator Elizabeth Warren’s (D-MA) office in the Hart building. Questions are raised about how the Cancer Drug Coverage Parity Act would affect patients with Medicare or Medicaid (rather than private insurance). In asking for help urging CMS to research E&M codes, Dr. Bering explains that the current codes for determining payment – which were set up in the 1980s – are outdated. Dr. Kleinerman adds: “We need more research because our patients are very complicated, very sick, and all different.” Dr. Bering speaks about the need for more research to re-examine evaluation and management codes. “No two patients are the same.” —DR. KLEINERMAN ASHClinicalNews.org ASH Clinical News 35